Bendamustine

Nature Reviews Drug Discovery

Volumn 7, Issue 6, 2008, Pages 473-474

  Keating, Michael J ^a   Yasothan, Uma ^b   Bach, Christian ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; TREANDA;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG STRUCTURE; HUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR STRUCTURE; NITROGEN MUSTARD COMPOUNDS; TREATMENT OUTCOME;

EID: 44449147770     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2596     Document Type: Article

References (13)

1. Dighiero, G. & Hamblin, T. J. Chronic lymphocytic leukaemia. Lancet 371, 1017-1029 (2008).
2. Lin, T. S. et al. Changing the way we think about chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4009-4012 (2005).
3. Chabber, B. A. & Roberts, T. G. Jr. Chemotherapy and the war on cancer. Nature Rev. Cancer 5, 65-72 (2005).
4. Leoni, L. M. et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 14, 309-317 (2008).
5. Bergmann, M. A. et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica 90, 1357-1364 (2005).
6. Food and Drug Administration. FDA labelling information [online], (2008).
7. Keating, M. J. et al. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74, 19-25 (1989).
8. Hillmen, P. et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25, 5616-5623 (2007).
9. Byrd, J. C. et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101 6-14 (2003).
10. Tam, C. et al. Long-term results of the fludarabine, cyclophosphamide and rituximab regimen as an initial therapy of chronic lymphocytic leukemia. Blood (in the press).
11. Morton, L M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107, 265-276. (2006)
12. National Cancer Institute. Cancer statistics [online], .
13. IMS Oncology Analyzer (2008).